# Regina Graul, Ph.D., Promoted to Chief Executive Officer
Canonical URL: https://biopharmsignal.com/news/CYCN/regina-graul-ph-d-promoted-to-chief-executive-officer
Ticker: CYCN
Company: Cyclerion
Source: Cyclerion
Published: 2024-08-07 11:00 EST
Original Source URL: https://ir.cyclerion.com
## Summary

CAMBRIDGE, Mass. , Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul , Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December

## Article Body
CAMBRIDGE, Mass. , Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul , Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December
## Recent Company News
- 2026-04-01 11:05 EST — [Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement](https://biopharmsignal.com/news/CYCN/cyclerion-therapeutics-and-korsana-biosciences-announce-merger-agreement) — Source: Cyclerion
- 2026-02-17 12:00 EST — [Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board](https://biopharmsignal.com/news/CYCN/cyclerion-therapeutics-announces-progress-toward-cyc-126-phase-2-proof-of-concept-study-with-fda-feedback-and-formation-of-clinical-advisory-board) — Source: Cyclerion
- 2026-01-05 21:01 EST — [Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression](https://biopharmsignal.com/news/CYCN/cyclerion-therapeutics-announces-strategic-agreement-with-medsteer-and-progress-toward-initiating-phase-2-proof-of-concept-study-for-cyc-126-in-treatment-resistant-depression) — Source: Cyclerion
- 2025-09-23 20:01 EST — [Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company](https://biopharmsignal.com/news/CYCN/cyclerion-announces-transformational-relaunch-as-a-neuropsychiatric-company) — Source: Cyclerion
- 2024-12-17 13:08 EST — [Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth](https://biopharmsignal.com/news/CYCN/cyclerion-s-sgc-stimulator-portfolio-generates-revenues-to-enable-company-growth) — Source: Cyclerion
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)